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the vitamin D deficient: results from the CIPRIS
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Background: Observational studies suggest vitamin D deficiency may contribute to the risk of acute infections. We
undertook a randomised controlled trial (RCT) of cholecalciferol supplementation as an intervention against acute
infections.
Methods: A cohort of 34 healthy adults was randomised to 20,000 IU/week cholecalciferol or identical placebo and
followed for 17 weeks during winter 2012. Acute infections, defined as the occurrence of sustained (at least an
hour) infection symptoms, either of severity 2/5 or greater or sustained over 24 h, were monitored by daily online
symptom reporting, with potential infections assessed in clinic. No microbiological verification of symptoms was
available, however. Primary endpoint was the occurrence of acute infection; secondary endpoints were infection
duration and infection severity; and tertiary endpoints were change in serum 25-hydroxyvitamin D (25(OH)D) and
adverse events.
Results: No treatment effect was observed for infection risk (HR: 0.83, 95% CI: 0.53, 1.31), nor duration or severity.
However, on stratification by baseline serum 25(OH)D (levels chosen on the basis of average levels in our cohort
and known minimums needed for bone health), a significant treatment effect on infection risk was evident among
those who were vitamin D deficient at the start of the study, such that those of baseline 25(OH)D < 40 nmol/L
(n = 4) realised a 44% reduction in infection risk (HR: 0.56; 95% CI: 0.32, 0.96; P = 0.007), this increasing to 73% on
restriction to clinically verified infections (HR: 0.27; 95% CI: 0.07, 1.00; P = 0.050). A similar but less consistent and
nonsignificant effect was seen for infection severity. Treatment was associated with significantly higher 25(OH)D
compared to placebo; however, the maximum 25(OH)D was 154 nmol/L and no adverse events occurred.
Conclusions: The results of this study suggest a protective effect of vitamin D supplementation against acute
infection risk among persons who are vitamin D deficient. Larger studies are needed to validate these findings.
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Acute infections, particularly respiratory tract infections
(RTIs), are a major cause of mortality, particularly among
those at the extremes of age and those requiring signifi-
cant support [1,2]. Moreover, RTIs are among the most
frequent sources of absenteeism from work and school,
accounting for millions of lost work and school days and
billions of lost wages each year [3]. Thus, an intervention
to reduce the frequency of acute infections is indicated.
A significant modulator of the immune response is
vitamin D’s active metabolite, 1,25-dihydroxyvitamin D,
which has been shown to regulate antimicrobial peptides
that comprise a significant part of the innate immune re-
sponse and is known to modulate the expression of nearly
1,000 genes [4,5]. In persons who are vitamin D deficient,
as occurs in winter at high latitudes and year-round for
long-term medical inpatients [6,7], there is a potential for
significant dysfunction in the innate immune response,
leading to a greater frequency of infections.
This has been supported by observational studies,
which found a potent relationship between vitamin D
deficiency and acute infection [8-13]. Randomised con-
trolled trials (RCTs) of cholecalciferol supplementation
have had mixed results, however, with some finding
protective treatment effects [14-17] and others not [18-20],
reflecting in part varied methodologies. Recently, Murdoch
and colleagues ran a 2-year trial of monthly cholecalciferol
supplementation for 18 months in 322 healthy adults, with
comprehensive monitoring of infections and clinical as-
sessment, but finding no difference in infection occur-
rence, duration or severity [20]. Despite some null
findings, systematic reviews [21,22] have indicated a
potential protective effect against infections from vita-
min D supplementation.
We hypothesised that by improving the vitamin D suf-
ficiency of participants, their innate immune response
would more effectively clear pathogens prior to their es-
tablishing a solid colonisation, reducing the occurrence
of symptomatic infections. Therefore, we undertook a
pilot RCT of 20,000 IU/week cholecalciferol vs. placebo in
a cohort of 34 adults to evaluate its efficacy at reducing
the frequency, duration and severity of acute infections.
Methods
Recruitment and follow-up
CIPRIS (Cholecalciferol Intervention to Prevent Respira-
tory Infections Study) was a double-blind randomised
placebo-controlled trial of 20,000 IU/week cholecalciferol
supplementation, undertaken in Hobart, Australia (lati-
tude 42.9°S). This dose was chosen with a goal to give the
equivalent of roughly 3,000 IU per day to realise a replete
25(OH)D status. The study was registered at www.clinical
trials.gov (NCT01549938) and the Australia-New Zealand
Clinical Trials Register (ACTRN12612000054819). Thestudy was approved by the Southern Tasmania Human
Research Ethics Committee, conforming to the principles
embodied in the Declaration of Helsinki. All participants
provided written informed consent. The study protocol
was developed and finalised prior to the start of recruit-
ment. No alterations to protocol were made during the
study recruitment or follow-up periods.
Study methods, results and interpretations thereof are
presented as per the CONSORT guidelines (Additional
files 1 and 2).
Participants were recruited from the student and staff
and their friends and families of the Menzies Research
Institute Tasmania and the University of Tasmania
School of Medicine, the Royal Hobart Hospital and the
TasTAFE Campbell Street Campus, all essentially healthy
controls representative of the general population. All
clinics were conducted at the Menzies Research Institute
Tasmania, however. Recruitment was in March-June
2012 conducted via flyers, email invitation and word-of-
mouth communication. Exclusion criteria were 1) age <18
or >60 years; 2) using immunomodulatory medication; 3)
diagnosed with an autoimmune, immune-deficiency or
chronic respiratory condition; 4) diagnosis of hyper-
calcemia or malabsorption syndrome, or any parathyroid,
liver or kidney disorder; 5) using vitamin D supplements
(>1,000 IU/day) in the preceding 3 months; 6) being
pregnant or planning to so within the study period;
7) inability to swallow capsules; or 8) inability to provide
informed consent. Interested persons were invited to
complete an online assessment questionnaire querying the
exclusion criteria, with acceptable participants asked to
provide contact information for the study investigators
to contact them on. Of the 173 persons who accessed
the assessment questionnaire, 52 were ineligible and
89 either did not provide contact information or de-
clined to participate on discussing the study protocol,
leaving 32 participants.
Follow-up was during the winter months, from May to
October 2012, much of which is when ambient UV is
too low to generate vitamin D [7].
At baseline assessment, participants were queried for
demographic information and diet and behaviour affect-
ing infection or vitamin D. At weekly updates, partici-
pants were queried about changes in health status,
medication, supplements, health status, or time outside
or physical activity.
Participants were also queried whether they had travel
out of the state in the interval since the last weekly up-
date. Excluding these people did not materially affect
any analyses (data not shown).
Sample size for this pilot was set at 32 to allow a bal-
ance between treatment arms, with the number selected
to test methods and principals in anticipation of a larger
study. Participants were a convenience sample of healthy
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min D deficiency or infection susceptibility.
Randomisation and treatment
Participants were randomised simply 1:1 to parallel
treatment using a computerised randomisation program
(www.randomization.com), using the first generator. A
person outside the study was asked to run the random-
isation and to affix the treatment labels with study IDs
to the respective bottles of treatment and placebo.
Cholecalciferol and placebo capsules were obtained
from Dartnells Pharmacy in Victoria, Australia. Both cho-
lecalciferol and placebo were identical white capsules.
Treatment allocations were dispensed at weekly clinics.
Blinding
As a double-blind RCT, all CIPRIS staff (including nurses
and database entry personnel), investigators and partici-
pants were blinded to treatment allocation until the con-
clusion of follow-up.
Biological specimens
At each monthly review, a blood sample was taken from
participants for measuring 25(OH)D. The first two monthly
specimens were also tested for corrected calcium and phos-
phate. Blood samples were centrifuged and the serum ali-
quoted and stored at −80°C until analysis.
Biological assays
Serum corrected calcium and phosphate were assessed
using standard methods by the Pathology Department of
the Royal Hobart Hospital each week.
After the conclusion of the study, serum 25(OH)D was
assessed by tandem mass spectroscopy by Canterbury
Health Laboratories in New Zealand.
Infection assessment
Participants completed daily online questionnaires query-
ing the occurrence and magnitude (0–5, where 0 is no
presence of that symptom and 5 is most severe) of acute
infection symptoms, including respiratory, gastrointes-
tinal, urinary tract, eye, ear, skin and cold sore infections,
as well as nonspecific symptoms. Online questionnaire
responses were monitored each day by the chief in-
vestigator. When a participant reported symptoms of
magnitude greater than 2/5 (thought to be of sufficient
magnitude for a single day’s occurrence to warrant assess-
ment in clinic), or two successive days of symptoms of any
magnitude, the participant was invited to come into clinic
for objective assessment by our study nurse.
After the conclusion of the study, infection reports
from daily online surveys, and from clinic assessments,
were reviewed by the chief investigator and the study
nurse, classifying infections and infection type. In theevent of disagreement between reviewers, infection status
was agreed upon by discussion. Respiratory, gastrointes-
tinal, urinary tract, eye, skin and cold sore infections were
defined by symptoms reflective of these infection types.
Ear infections were defined as earache symptoms in the
absence of RTI symptoms. Systemic/nonspecific infections
were defined as nonspecific symptoms like fever, malaise,
fatigue, headache, and/or arthromyalgia, in the absence of
other infection symptom types.
Infection duration was defined from the first day of re-
ported symptoms and concluded at the resolution of symp-
toms. Where infections were confluent, a judgement was
made on the basis of symptoms and symptom severities as
to the end of one infection and start of another.
Infection severity for each infection was evaluated in
three fashions. One was to take the maximum reported
infection symptom severity for that infection. We also
summated the infection severity scores for all infection
symptoms for each day of the infection and summated
this for a total infection severity score. Finally, we averaged
the daily total infection symptom severities. For RTIs, only
RTI-specific symptoms were used.
While the majority of infections were seen in clinic, a
subset (11.8%) was only reported on online daily ques-
tionnaire but not seen in clinic. Sub-analyses excluding
these are reported.Adverse events
Serum collected at the first 2 months was evaluated for
the levels of corrected calcium and phosphate. These re-
ports were reviewed by an external monitor, who could
terminate a participant’s participation if levels exceeded
safe levels.
In addition, on daily questionnaire and at weekly and
infection clinics, participants were queried about the oc-
currence and severity (0–5) of symptoms potentially indi-
cative of hypercalcemia or hyperphosphatemia, including
excessive thirst, abnormally high urine output, change in
urine colour, bone pain, groin-area pain, confusion, irrit-
ability or other neurological symptoms. Any sustained oc-
currence of these could have resulted in that subject’s
participation being stopped.Statistical analyses
Analysis was by intention-to-treat.
Primary outcomes were time to infection. Secondary
outcomes were infection severity and duration. Tertiary
outcomes were change in serum 25(OH)D and the oc-
currence of adverse events.
Predictors of time-to-acute infection were assessed by
survival analysis, using Cox proportional hazard models
for repeated events [23]. All covariates satisfied the pro-
portional hazard assumption.
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and inter-review interval duration were evaluated by
Kruskal-Wallis rank test.
Predictors of having an infection during the study
were evaluated by logistic regression.
Predictors of infection duration, infection severity and
longitudinally measured 25(OH)D were assessed by multi-
level mixed effects linear regression. Predictors of infection
count during the study were assessed by linear regression.
Predictors of baseline-measured 25(OH)D were assessed
by linear regression. As the distribution of all these vari-
ables was skewed, transformation was applied as required
to satisfy homoscedasticity; however, all coefficients are re-
ported on the scale of the original value.
Where interaction was assessed, a product term con-
taining the primary predictor and the interaction covari-
ate was generated and included in the model.
For all instances where data was missing, analyses were
restricted to persons with complete data.




We initially recruited 32 participants, the majority (23/32)
attending their first clinic in the 2 weeks of the study. Two
participants (both on treatment) dropped out during the
study due to not being able to meet the study’s schedule
rigour (one after week 1, the other after week 4), and these
were replaced with an additional two participants who ran
out their period of follow-up. Analyses excluding these
additional two participants did not materially affect the re-
sults (data not shown).
Participants were followed for an average of 16.4 weeks.
Follow-up time did not differ significantly between treat-
ment groups (treatment: 15.7 weeks; placebo: 17.2 weeks;
P = 0.10). While the interval between reviews (not in-
cluding infection clinics) was 7 days, there was some
variation in this, with a mean interval of 7.07 days; this
interval did not significantly differ between treatment
groups (P = 0.77).
Over the course of an average follow-up, 34 partici-
pants experienced 98 infections. Of these, the majority
(69.4%) were RTIs. Virtually everyone in the cohort had
at least one infection (31/34, 91.2%)—six people had one
infection, eight had two infections, seven had three in-
fections and ten had four or more infections.
As in Table 1, the cohort was majority female, majority
Australian-born and of mean age 32 years. None of the
cohort characteristics were significantly different be-
tween treatment arms. A small number of participants
(two on treatment, one on placebo) reported taking mul-
tivitamins, but otherwise no one was taking any supple-
ments which might contain vitamin D.Predictors of infection, infection duration and severity
Having any infection during the study was less frequent
among those on treatment (OR: 0.53; 95% CI: 0.04, 6.51),
though this was not statistically significant. Infection
count was lower among those on treatment (mean: 2.01;
95% CI: 1.12, 2.89) than those on placebo (mean: 3.01;
95% CI: 1.87, 4.15), though this did not reach statistical
significance (P = 0.17). On restriction to infections seen in
clinic, this difference was increased but still did not reach
statistical significance (P = 0.13). These analyses could
not be stratified by baseline-measured 25(OH)D. Overall,
there was no evidence of statistically significant treatment
effects on infection overall.
Hazard of infection was not significantly predicted by
treatment (Table 2) nor was infection duration or infec-
tion severity by any of the measures used.
While there was no significant effect on infection hazard
by treatment overall, on stratification by baseline-measured
serum 25(OH)D, a protective effect from treatment became
evident among those who were deficient at the start of the
study (Table 3). This effect was strongest on setting the
threshold at 40 nmol/L (pinteraction = 0.042), attenuating at
a threshold of 50 nmol/L (pinteraction = 0.68) and disappear-
ing altogether at a threshold of 60 nmol/L (pinteraction =
0.40). On restriction to infections which were seen in
clinic, these trends were increased in magnitude, though
of reduced significance, likely reflecting the decreased
number of infections. Associations persisted on adjust-
ment. On restriction to RTIs, trends were similar (data
not shown). Importantly, any protective effect was abro-
gated on adjustment for extant levels of serum 25(OH)D,
indicating a true effect of treatment via increasing
25(OH)D (data not shown).
On stratification by baseline-measured 25(OH)D, no
effect of treatment on infection duration was apparent.
For infection severity, on stratification by level of base-
line 25(OH)D, there were inconsistent trends for the
maximum infection severity score and the average daily
infection severity score, but no trend was apparent for
the total infection severity score (Additional file 3). Simi-
lar results were found for RTIs seen in clinic (data not
shown). No associations were found for infections not
seen in clinic (data not shown).
Distribution and predictors of serum vitamin D
The mean 25(OH)D at study entry was 67.9 nmol/L (SD:
23.0), with those randomised to treatment having signifi-
cantly lower baseline 25(OH)D than those allocated
to placebo (60.5 vs. 76.4, P = 0.040). Thereafter, the mean
25(OH)D for those on treatment was 100.7 nmol/L (SD:
23.9), while that of placebo was 56.0 nmol/L (SD: 24.2) (P <
0.001). Trends in 25(OH)D over time are shown in Figure 1.
There was a negative interaction between baseline-
measured BMI and treatment in predicting 25(OH)D,
Table 1 Distribution of cohort characteristics, overall and between treatment allocations
Placebo
n = 16 (47.1%)
Treatment
n = 18 (52.9%)
Total infections during the study 54 44
Infection type
Respiratory tract infection 32 (59.3) 36 (81.8)
Gastrointestinal infection 11 (20.4) 5 (11.4)
Urinary tract infection 0 0
Skin infection 2 (3.7) 0
Ear infection 1 (1.9) 0
Eye infection 0 1 (2.3)
Cold sore 5 (9.3) 2 (4.6)
Systemic/nonspecific 3 (5.6) 0
Sex
Male 5 (31.3) 9 (50.0)
Female 11 (68.8) 9 (50.0)
Birthplace
Australia 15 (88.2) 14 (82.4)
New Zealand 1 (5.9) 1 (5.9)
United Kingdom 0 2 (11.8)
Singapore 1 (5.9) 0
BMI at baseline
< 18.5 1 (6.3) 0
18.5–24.9 8 (50.0) 10 (55.6)
25.0–29.9 6 (37.5) 7 (38.9)
30 or greater 1 (6.3) 1 (5.6)
Taking any medications at baseline?
No 9 (56.3) 9 (50.0)
Yes 7 (43.8) 9 (50.0)
Taking any supplements at baseline?
No 12 (75.0) 15 (83.3)
Yes 4 (25.0) 3 (16.7)
Ever smoked?
No 12 (75.0) 15 (83.3)
Yes 4 (25.0) 3 (16.7)
How much time do you usually spend in the sun on weekends and holidays in summer?
< 30 min/day 1 (6.3) 1 (5.6)
30–60 min/day 2 (12.5) 3 (16.7)
1–2 h/day 6 (37.5) 4 (22.2)
2–3 h/day 5 (31.3) 4 (22.2)
3–4 h/day 2 (12.5) 4 (22.2)
4 or more hours/day 0 2 (11.1)
Age 35.0 (12.5; 19–51) 30.3 (11.8; 18–52)
Baseline 25(OH)D (nmol/L) 76.4 (27.3; 36–132) 60.5 (13.9; 32–78)
Results for categorical and dichotomous variables are presented at n (%). Results for age and baseline 25(OH)D are presented as mean (SD; range). Significance of
difference in dichotomous or categorical variables between treatment arms is assessed by chi-square test. Significance of difference in continuous variables between
treatment arms is assessed by Kruskal-Wallis test.
25(OH)D 25-hydroxyvitamin D, nmol/L nanomoles per litre.
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Table 2 Treatment predicting infection hazard, infection duration and infection severity
All infections Infections seen in clinic All URTIs URTIs seen in clinic
n = 98 (54 placebo;
44 treatment)
n = 63 (34 placebo;
29 treatment)
n = 68 (32 placebo;
36 treatment)
n = 55 (28 placebo;
27 treatment)
Infection hazard (HR (95% CI)) Placebo 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 0.83 (0.53, 1.31) 0.86 (0.50, 1.50) 1.11 (0.75, 1.65) 0.98 (0.59, 1.63)
P = 0.42 P = 0.60 P = 0.62 P = 0.94
Infection duration
(coefficient (95% CI))
Placebo 3.05 (2.35, 3.76) 4.15 (2.77, 5.53) 4.87 (3.29, 6.45) 5.28 (3.38, 7.18)
Treatment +1.04 (−0.25, 2.32) +1.64 (−0.83, 4.11) +0.51 (−1.80, 2.81) +0.83 (−2.05, 3.70)
P = 0.11 P = 0.19 P = 0.67 P = 0.57
Maximum infection symptom
severity (coefficient (95% CI))
Placebo 2.19 (1.81, 2.57) 2.19 (1.69, 2.70) 2.41 (1.89, 2.93) 2.42 (1.85, 3.00)
Treatment +0.08 (−0.49, 0.65) +0.19 (−0.58, 0.95) +0.03 (−0.69, 0.76) −0.05 (−0.85, 0.76)
P = 0.79 P = 0.63 P = 0.93 P = 0.91
Total infection severity
(coefficient (95% CI))
Placebo 12.26 (7.90, 16.62) 20.34 (9.01, 31.67) 25.47 (11.51, 39.43) 29.34 (12.28, 46.40)
Treatment +2.20 (−5.09, 9.49) +5.95 (−13.15, 25.05) −3.89 (−21.83, 14.06) −2.87 (−25.70, 19.96)
P = 0.55 P = 0.54 P = 0.67 P = 0.81
Average daily total infection
symptom severity
(coefficient (95% CI))
Placebo 4.00 (3.25, 4.75) 4.74 (3.52, 5.96) 5.28 (3.73, 6.82) 5.41 (3.81, 7.02)
Treatment −0.26 (−1.34, 0.82) −0.22 (−1.97, 1.52) −1.08 (−3.00, 0.85) −0.91 (−2.98, 1.16)
P = 0.64 P = 0.80 P = 0.27 P = 0.39
Infection hazard results are presented as HR (95% CI). Results for infection duration and severity are reported as geometric mean infection severity (95% CI) and
then coefficient relative to the placebo group (95% CI). Note: a greater infection severity score or greater infection duration means a more severe infection or
longer duration, respectively.




at level specified (%)
All infections Infections seen in clinic
Unadjusted Adjusteda Unadjusted Adjusteda
All persons Placebo 16 (47.1) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
0.83 (0.53, 1.31) 0.80 (0.50, 1.30) 0.86 (0.50, 1.50) 0.87 (0.52, 1.46)
Treatment 18 (52.9) P = 0.42 P = 0.37 P = 0.60 P = 0.60
25(OH)D threshold (nmol/L) ≤40 Placebo 2 (50.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 2 (50.0) 0.56 (0.32, 0.96)b 0.41 (0.22, 0.78)b 0.27 (0.07, 1.00)b 0.26 (0.06, 1.17)
P = 0.036b P = 0.007b P = 0.050b P = 0.079
≤50 Placebo 4 (50.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 4 (50.0) 0.61 (0.38, 0.98)b 0.68 (0.34, 1.34) 0.48 (0.18, 1.30) 0.57 (0.18, 1.78)
P = 0.043b P = 0.27 P = 0.15 P = 0.34
≤60 Placebo 4 (40.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 6 (60.0) 0.86 (0.54, 1.35) 1.02 (0.60, 1.72) 0.66 (0.34, 1.30) 0.74 (0.36, 1.56)
P = 0.50 P = 0.95 P = 0.23 P = 0.43
≤70 Placebo 5 (29.4) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 12 (70.6) 0.80 (0.51, 1.25) 0.82 (0.48, 1.41) 0.95 (0.46, 1.97) 0.85 (0.42, 1.70)
P = 0.33 P = 0.48 P = 0.89 P = 0.64
Results are presented as HR (95% CI).
25(OH)D 25-hydroxyvitamin D, nmol/L nanomoles per litre.
aAnalyses adjusted for age, sex, ever smoking and days per week engaging in vigorous physical activity.
bStatistically significant.
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Figure 1 Trends in serum 25(OH)D by treatment group.
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cant increase in 25(OH)D (mean increase: 30.0; 95% CI:
15.2, 44.8; P = 0.001), while those of higher BMI (25.0–
29.9) realised a 21.2 increase (95% CI: 7.3, 35.0; P = 0.003),
and those of the highest BMI (30 or greater) did not have
a significant increase in their 25(OH)D from treatment
(mean increase: 12.9; 95% CI: −14.6, 40.4; P = 0.36). While
not statistically significant (test for difference: P = 0.40),
the difference was appreciable and persisted on adjust-
ment for age, sex and physical activity.
Interestingly, there was also a significant positive inter-
action between sex and treatment in predicting 25(OH)D,
such that females realised nearly three times greater
25(OH)D from treatment (mean increase: 36.7; 95% CI:
23.0, 50.5; P < 0.001) than males (mean increase: 12.5; 95%
CI: −3.4, 28.5; P = 0.12) (test for difference: P = 0.04), des-
pite virtually identical levels by sex among those on pla-
cebo. This effect persisted on adjustment for age, physical
activity and BMI.
Adverse events
No participants suffered from hypercalcemia or hyperpho-
sphatemia as determined by blood test. No participants re-
ported any symptoms indicative of adverse events.
Treatment guess
There was no evidence of loss of blinding (data not shown).Discussion
In this pilot RCT, we have shown evidence of a protect-
ive effect of 20,000 IU/week cholecalciferol supplemen-
tation against acute infection among persons who were
vitamin D deficient at baseline. Treatment realised sig-
nificantly higher 25(OH)D compared to placebo. While
no significant effect of treatment on infection was seen in
the aggregate, among those who were vitamin D deficient
at the start of the study, a significant protective effect from
treatment was evident. Importantly, the magnitude of ef-
fect was enhanced on restriction to infections which were
assessed in clinic, and associations disappeared on adjust-
ment for serum 25(OH)D. A similar but less consistent
interaction by level of baseline 25(OH)D was seen for in-
fection severity. No treatment effect on infection duration
was found. None of our cohort members experienced ad-
verse effects, and the highest 25(OH)D was 154 nmol/L.
Since our cohort was comprised of healthy adults in a
Western nation, its generalisability extends to similarly sit-
uated Western healthy adults.
While no effect of treatment is apparent in the aggre-
gate, a significant protective effect was present among
those who were vitamin D deficient at baseline. This ef-
fect among the deficient is similar to a trial of vitamin D
supplementation as an intervention against exacerba-
tions of COPD, which found efficacy only among those
with 25(OH)D < 25 nmol/L [24]. Ours is the first trial of
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acute infections in vitamin D-deficient healthy adults.
Murdoch and colleagues examined their infection analyses
by level of baseline 25(OH)D of 50 nmol/L but reported
no significant interactions [20]. Rees and colleagues also
examined treatment effect by level of baseline 25(OH)D
but found no protective effect among the deficient, though
this may be due to the low dose used in that trial
(1,000 IU/day) [19].
The protective effect on acute infection was clearest
and most pronounced for infection risk. A similar but
less consistent effect was seen for infection severity. The
inconsistency of the trends of associations may indicate
that no association exists with severity. However, sever-
ity was necessarily reported by participants, and the vari-
ability between participants as to what is severe no
doubt affected the quality of the measure.
While no effect of treatment was evident for infection
duration, this is not unexpected. Our hypothesis was that
vitamin D enables the effective responsiveness of innate
immune system pathways and thus improves the ability of
the body to block the colonisation by pathogens [4,25-30],
so an effect of vitamin D on absolute infection risk was
expected. Vitamin D also has the capacity to depress in-
flammatory immune pathways like IP-10 and IL-8 [31,32],
enabling an effective but less inflammatory response.
Thus, an effect on infection severity is expected from vita-
min D sufficiency. Once a pathogen has already secured a
hold, however, the duration of infection is a function of
the efficiency of the immune response and the characteris-
tics of the aetiologic pathogen and thus more independent
of vitamin D status.
On evaluating the impact of treatment on serum 25(OH)D,
some interesting differences were seen by level of BMI
and by sex, such that treatment was less impactful on
25(OH)D among those of higher BMI, while females had
a greater increase in 25(OH)D from treatment. The differ-
ence by BMI is not surprising, given the vitamin D hoard-
ing of adipose tissue would keep serum 25(OH)D lower
than might occur in those of lower BMI [33,34], and
others have demonstrated this as well [35]. However, the
difference by sex was unexpected and not easily explained.
Certainly, it is possible that females have a differential vita-
min D metabolism than males, as has been demonstrated
by others [36].
Our study’s methodology compares favourably with
many of those undertaken previously. We designed our
method to improve upon the designs reported in publica-
tions prior to when we undertook our study [14,18], which
relied on passive detection. Our use of daily online follow-
up to detect infections as close to the start of infection as
possible, followed by objective assessment, was designed
to allow an accurate and sensitive detection, while not
affecting adherence. These methods are similar to that ofMurdoch and colleagues [20] and to a lesser extent that
of Rees and colleagues; however, these still relied on
participant reporting. By placing the onus for detection
on the study investigators, more infections may be de-
tected closer to symptom onset. By relying on participants
to report symptoms via daily questionnaire, the subjective
nature of what is a reportable symptom is still a limitation.
Our hypothesis that vitamin D enhances the efficiency
of the innate immune system to block colonisation by
pathogens could not be evaluated due to the absence of
pathogen sampling data. This is a limitation since it pre-
cluded our evaluation of pathogens present during infec-
tion or validation of infectious aetiology of symptoms.
Further to this, our not obtaining valid nasal swab data
to assess the aetiological pathogen and substantiate in-
fection symptoms as a true infection is a limitation. The
high frequency of infections during the study may indi-
cate that some of the infections reported, particularly
those not assessed in clinic, were not true infections.
However, that we saw a potentiation in the treatment ef-
fect among the deficient on restricting to infections seen
in clinic is supportive of a true effect, as this necessarily
removes some symptoms which were not true infections.
Another limitation is that our greatest impact of treat-
ment was among a subgroup with only four people.
While they comprised an appreciable proportion of our
cohort (11.8%), this is nonetheless a small number. How-
ever, in addition to the statistical significance of this asso-
ciation, we think that the attenuation in association as the
threshold of sufficiency is raised and that the treatment ef-
fect is enhanced on restriction to infections assessed in
clinic are supportive of a true association, rather than
artifact. Another measure that would have strengthened
this study was to measure levels of activated vitamin D
and antimicrobial peptides in the respiratory tract, which
would have helped support the causality of a treatment ef-
fect. Finally, a small number (n = 3; two treatment, one
placebo) reported taking multivitamins during the study,
while four participants (all on placebo) started taking fish
oil during the study (two at week 1, one at week 3, one at
week 13), none of whom were also taking multivitamins.
Consequently, there was some nontreatment supplemen-
tation of vitamin D, though of a relatively minor level (400
to 1,000 IU). Given the preponderance of fish oil use
among controls, any impact of this would have been to re-
duce the difference in serum 25(OH)D over time, a reduc-
tion that if present was quite small indeed. Moreover, if
there was a reduction in the spread of serum 25(OH)D be-
tween treatment arms, then potentially the observed re-
ductions in infection risk may be an underestimate.
Conclusions
Our results from this pilot trial of weekly cholecalciferol
supplementation vs. placebo among a cohort of 34 healthy
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against acute infection risk among those which started
the study vitamin D deficient. This effect persisted on
adjustment for potential confounders, and the trends
found on raising the threshold of deficiency/sufficiency
and on restricting to infections seen in clinic are suggest-
ive of a true effect. A larger study is needed to validate
these results, and graded doses of supplementation are ne-
cessary to delineate the most optimal dose to realise a re-
duction in acute infection risk.
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